Search

Your search keyword '"Romagnoli, V."' showing total 161 results
Start Over Author "Romagnoli, V." Language english
161 results on '"Romagnoli, V."'

17. HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial

Author

Almasio, P., Colombatto, P., Brunetto, M., Maina, A., Romagnoli, V., Rumi, M., Ascione, A., Pinzello, G., Mondelli, M., Muratori, L., Rappuoli, R., Rosa, D., Houghton, M., Abrignani, S., Bonino, F., Almasio, PL, Colombatto, P, Brunetto, MR, Maina, AM, Romagnoli, V, Almasio, P, Rumi, MG, Ascione, A, Pinzello, G, Mondelli, M, Muratori, L, Rappuoli, R, Rosa, D, Houghton, M, Abrignani, S, and Bonino, F

Subjects
HCV vaccine
Abstract

Hepatitis C virus (HCV) vaccines may be able to increase viral clearance in combination with antiviral therapy. We analysed viral dynamics and HCV-specific immune response during retreatment for experienced patients in a phase Ib study with E1E2MF59 vaccine. Seventy-eight genotype 1a/1b patients [relapsers (30), partial responders (16) and nonresponders (32) to interferon-(IFN)/ribavirin-(RBV)] were randomly assigned to vaccine (V:23), Peg-IFNα2a-180-ug/qw and ribavirin 1000-1200-mg/qd for 48 weeks (P/R:25), or their combination (P/R + V:30). Vaccine (100 μg/0.5 mL) was administered intramuscularly at week 0-4-8-12-24-28-32-36. Neutralizing of binding (NOB) antibodies and lymphocyte proliferation assay (LPA) for E1E2-specific-CD4 + T cells were performed at week 0-12-16-48. Viral kinetics were analysed up to week 16. The vaccine was safe, and a sustained virological response (SVR) was achieved in 4 P/R + V and 2 P/R patients. Higher SVR rates were observed in prior relapsers (P/R + V = 27.3%; P/R = 12.5%). Higher NOB titres and LPA indexes were found at week 12 and 16 in P/R + V as compared to P/R patients (P = 0.023 and 0.025, P = 0.019 and

Published
2014

18. HBsAg kinetics during and after nucleos(t)ide analogues described by mathematical modeling.

Author

Colombatto, P., Civitano, L., Coco, B., Cavallone, D., Oliveri, F., Ricco, G., Santucci, M., Damone, F., Romagnoli, V., Salvati, A., Surace, L., Bleve, P., Bonino, F., and Brunetto, M.R.

Abstract

HBsAg clearance (functional cure) is the optimal endpoint of chronic hepatitis B treatment. Nucleo(s)tide analogues (NAs) have a limited impact on HBsAg decline, however achieving low HBsAg serum levels correlates with loss after discontinuation. To investigate mechanisms of HBsAg decline during NAs. We set up a mathematical model describing: 1) dynamics of replication-competent hepatocytes (cccDNA>1 copy/cell) producing HBsAg by either cccDNA or integrated DNA (intDNA); 2) cccDNA turnover; 3) dynamics of non-replication-competent hepatocytes which lost cccDNA by cell division, but still produce HBsAg by intDNA. Baseline I 0-cccDNA and their immune-mediated clearance rate were computed by ALT decline upon NAs block of HBV replication; cccDNA lifetime by fitting ALT, HBV-DNA and HBsAg; HBsAg production rate constants (from I 0-cccDNA and I 0-intDNA), I 0-intDNA and their lifetime by fitting HBsAg. We applied the model in 29 HBeAg-neg and 2 HBeAg-pos patients, median age 56.1(30-76.6) years, 21(65.6%) males, 17(54.8%) with cirrhosis. Median NAs treatment was 123.1(41.2-260.1) months. HBV-DNA (COBAS-TaqMan, Roche) and HBsAg (Architect, Abbott) were tested every six months. HBsAg during NAs showed 3 different patterns: steady (3;9.6%), monophasic (18;58.1%) and multiphasic (10;32.3%) decline. Mean baseline ALT and HBsAg were lower in monophasic (121±95vs666±565 U/L, p=0.0004 and 4,421.9±2,876,2vs18,846.8±22,861.3 IU/mL, p=0.0272). Overall, 6(19.4%) lost HBsAg: 5(17.2%) HBeAg-neg (4 during, 1 after NAs) and 1 (50%) HBeAg-pos (after discontinuation-retreatment). Patients who lost HBsAg on-therapy had multiphasic declines, successfully described by the model (Figure). Monophasic patients had lower I 0-cccDNA (22.0%±15.4%vs54.8%±27.3%, p=0.0159) and HBsAg production by cccDNA (1.7%±2.3vs53.3%±27.3%, p<0.0001). Lifetime of I intDNA was longer in monophasic (3,938±2,681 vs 1,340±875 days, p=0.0065), cccDNA lifetime was similar (52±52vs31±14 days, p=0.2288). Mathematical modeling showed that faster HBsAg decline after NAs was associated with higher disease activity and prevalent HBsAg production from cccDNA, with lifetime shorter of intDNA. HBsAg loss was characterized by multiphasic declines. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Middle lobe syndrome in children today

Author

Romagnoli, V. Priftis, K.N. De Benedictis, F.M.

Abstract

Middle lobe syndrome in children is a distinct clinical and radiographic entity that has been well described in the pediatric literature. However, issues regarding its etiology, clinical presentation, and management continue to puzzle the clinical practitioner. Pathophysiologically, there are two forms of middle lobe syndrome, namely obstructive and nonobstructive. Middle lobe syndrome may present as symptomatic or asymptomatic, as persistent or recurrent atelectasis, or as pneumonitis or bronchiectasis of the middle lobe and/or lingula. A lower threshold of performing a chest radiograph is warranted in children with persistent or recurrent nonspecific respiratory symptoms, particularly if there is clinical deterioration, in order to detect middle lobe syndrome and to initiate a further diagnostic and therapeutic workup. © 2014 Elsevier Ltd.

Published
2014

24. Phenotype and disease course of early-onset pediatric inflammatory bowel disease

Author

Aloi, M, Lionetti, P, Barabino, A, Guariso, Graziella, Costa, S, Fontana, M, Romano, C, Lombardi, G, Miele, E, Alvisi, P, Diaferia, P, Baldi, M, Romagnoli, V, Gasparetto, M, DI PAOLA, M, Muraca, M, Pellegrino, S, Cucchiara, S, Martelossi, S, on behalf of SIGENP IBD Group, Marina, Aloi, Paolo, Lionetti, Arrigo, Barabino, Graziella, Guariso, Stefano, Costa, Massimo, Fontana, Claudio, Romano, Giuliano, Lombardi, Miele, Erasmo, Patrizia, Alvisi, Paolo, Diaferia, Maurizio, Baldi, Vittorio, Romagnoli, Marco, Gasparetto, Monica Di, Paola, Monica, Muraca, Salvatore, Pellegrino, Salvatore, Cucchiara, and Stefano, Martelossi

Subjects
Male, medicine.medical_specialty, Adolescent, early onset, Ulcerative, Disease, Inflammatory bowel disease, Severity of Illness Index, Crohn Disease, children, inflammatory bowel disease, Internal medicine, Severity of illness, medicine, Humans, Immunology and Allergy, Colitis, Family history, Age of Onset, Child, Preschool, Children, Early onset, Child, Preschool, Colitis, Ulcerative, Disease Progression, Female, Follow-Up Studies, Infant, Infant, Newborn, Phenotype, Gastroenterology, business.industry, medicine.disease, Newborn, Ulcerative colitis, digestive system diseases, Age of onset, business
Abstract

BACKGROUND: Early-onset (EO) pediatric inflammatory bowel diseases (IBD) seem to be more extensive than those with a later onset. To test this hypothesis, we examined the phenotype and disease course of patients with IBD diagnosis at 0 to 5 years, compared with the ranges 6 to 11 and 12 to 18 years. METHODS: Anatomic locations and behaviors were assessed according to Paris classification in 506 consecutive patients: 224 Crohn's disease, 245 ulcerative colitis, and 37 IBD-unclassified. RESULTS: Eleven percent of patients were in the range 0 to 5 years, 39% in 6 to 11 years, and 50% in 12 to 18 years. Ulcerative colitis was the most frequent diagnosis in EO-IBD and in 6- to 11-year-old group, whereas Crohn's disease was predominant in older children. A classification as IBD-unclassified was more common in the range 0 to 5 years compared with the other groups (P < 0.005). EO Crohn's disease showed a more frequent isolated colonic (P < 0.005) and upper gastrointestinal involvement than later-onset disease. Sixty-two percent of the patients in the 0 to 5 years range had pancolonic ulcerative colitis, compared with 38% of 6 to 11 years (P = 0.02) and 31% of 12-18 years (P = 0.002) range. No statistical difference for family history for IBD was found in the 3-year age groups. Therapies at the diagnosis were similar for all children. However, at latest follow-up, a significantly higher proportion of younger children were under steroids compared with older groups (P < 0.05). Surgical risk did not differ according to age. CONCLUSIONS: EO-IBD exhibits an extensive phenotype and benefit from aggressive treatment strategies, although surgical risk is similar to later-onset disease. A family history for IBD is not common in EO disease.

Published
2014

25. HCV E1E2-MF59vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial

Author

Colombatto, P, Brunetto, M R, Maina, A M, Romagnoli, V, Almasio, P, Rumi, M G, Ascione, A, Pinzello, G, Mondelli, M, Muratori, L, Rappuoli, R, Rosa, D, Houghton, M, Abrignani, S, Bonino, F, P. Colombatto, M. R. Brunetto, A. M. Maina, V. Romagnoli, P. Almasio, M. G. Rumi, A. Ascione, G. Pinzello, M. Mondelli, L. Muratori, R. Rappuoli, D. Rosa, M. Houghton, S. Abrignani, and F. Bonino

Subjects
CD4-Positive T-Lymphocytes, Squalene, Viral Hepatitis Vaccines, Drug-Related Side Effects and Adverse Reactions, viral kinetics, Polysorbates, VACCINE, Antiviral Agents, Injections, Intramuscular, immune response, Polyethylene Glycols, viral kinetic, Adjuvants, Immunologic, Ribavirin, Humans, neutralizing antibodies, HCV, interferon, vaccine, Cell Proliferation, Vaccines, Synthetic, Interferon-alpha, Original Articles, Hepatitis C Antibodies, Hepatitis C, Chronic, Viral Load, Antibodies, Neutralizing, Combined Modality Therapy, Recombinant Proteins, Treatment Outcome, RNA, Viral
Abstract

Hepatitis C virus (HCV) vaccines may be able to increase viral clearance in combination with antiviral therapy. We analysed viral dynamics and HCV-specific immune response during retreatment for experienced patients in a phase Ib study with E1E2MF59 vaccine. Seventy-eight genotype 1a/1b patients [relapsers (30), partial responders (16) and nonresponders (32) to interferon-(IFN)/ribavirin-(RBV)] were randomly assigned to vaccine (V:23), Peg-IFNα2a-180-ug/qw and ribavirin 1000–1200-mg/qd for 48 weeks (P/R:25), or their combination (P/R + V:30). Vaccine (100 μg/0.5 mL) was administered intramuscularly at week 0-4-8-12-24-28-32-36. Neutralizing of binding (NOB) antibodies and lymphocyte proliferation assay (LPA) for E1E2-specific-CD4 + T cells were performed at week 0-12-16-48. Viral kinetics were analysed up to week 16. The vaccine was safe, and a sustained virological response (SVR) was achieved in 4 P/R + V and 2 P/R patients. Higher SVR rates were observed in prior relapsers (P/R + V = 27.3%; P/R = 12.5%). Higher NOB titres and LPA indexes were found at week 12 and 16 in P/R + V as compared to P/R patients (P = 0.023 and 0.025, P = 0.019 and

Published
2014

35. Quantitative HBV/HDV markers help to distinguish different clinic/virologic phases of chronic hepatitis delta.

Author

Ricco, G., Cavallone, D., Oliveri, F., Colombatto, P., Damone, F., Coco, B., Vianello, B., Romagnoli, V., Salvati, A., Surace, L., Bonino, F., and Brunetto, M.R.

Abstract

New therapy options for Chronic hepatitis delta (CHD) urge a better clinical/virologic stratification of patients(pts). We quantified HDV/HBV markers to investigate their correlation with disease activity/stage in untreated and Interferon(IFN)-treated pts. One hundred forty-six consecutive anti-HDV+pts admitted at Pisa University Hospital were classified based on biochemical/histological/imaging data in:1)Pts without liver disease (no-CHD)[ALT<40U/L, LS<6kPa];2)CHD without cirrhosis;3)CHD with cirrhosis;4)CHD with advanced cirrhosis [varices/decompensation/HCC]. HDV-RNA (RoboGeneKit2.0;Roboscreen-Diagnostics), anti-HDV(Liaison®XLmurexAnti-HDV,DiaSorin) and HBV markers (HBV-DNA/HBsAg/HBcrAg/anti-HBc-IgG) were tested at baseline(BL) in the overall cohort, and at end-of-therapy(EOT),6-months after EOT (6mFU) and end-of-follow-up(EOF) in 31(21.2%) IFN-treated pts. Virologic response was defined by qualitative HDV-RNA (in house-PCR). Table1 shows the BL characteristics of the overall cohort. Eleven (7.6%) subjects were classified as no-CHD; 10/11(90.9%) had HDV-RNA serum levels(sl)<1000 IU/mL. Among 135 CHD pts, HDV-RNA sl were higher in pts with cirrhosis compared to CHD without cirrhosis or with advanced cirrhosis. All no-CHD subjects had anti-HDV titer≤1:100; 132/135 CHD pts (97.8%) had anti-HDV≥1:1000. At multivariate analyses, HDV-RNA[OR=1.816/P=0.007], anti-HDV[OR=4.429/P=0.012] and anti-HBc-IgG[O7R=3.260/P=0.041] associated with higher disease activity(ALT>100U/L); Age[OR=1.059/P=0.032] and HDV-RNA [OR=1.643/P=0.006] associated with cirrhosis. Among 31 IFN-treated-pts [duration 12.4(2.0/91.7) months], 13(41.9%) had virologic response, 3 (9.7%) relapsed and 15(48.4%) were non-responders at 6mFU. At EOF [median 4.6(1.3-18)years], 14 pts maintained undetectable qualitative HDV-RNA and normal ALT, all of them showing HDV-RNA sl<1000 IU/mL, 12/14 (85.7%) anti-HDV≤1:100. The remaining pts with CHD at EOF had HDV-RNA sl>1000 IU/mL and anti-HDV≥1:1000 in 92.3% and 100% of cases, respectively. In CHD pts HDV-RNA sl independently correlate with biochemical activity and stage of liver disease. HDV infection can persist without active liver damage in a status, either spontaneously-acquired or IFN-induced, characterized by low levels of viral replication (HDV-RNA<1000 IU/mL) and anti-HDV titer (≤1:100) The quantitative analysis of HDV/HBV markers qualifies as a useful tool for clinic-virological classification and treatment monitoring of CHD pts. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results